Treatments & Surgery
Share your love
International Glaucoma Symposium highlights the meeting point of practice and technology | Ophthalmology Times
The 2nd International Glaucoma Symposium underscores how AI and advanced imaging are becoming integral to modern glaucoma diagnosis and management. (Image credit: AdobeStock/OngCaLucK) The International Glaucoma Symposium was created to close the gap between cutting-edge research and real-world clinical decision-making…
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials | Ophthalmology Times
FDA approval of YUVEZZI marks the first dual-agent, daily eye drop option for adults seeking non-invasive presbyopia treatment. (Image credit: Ophthalmology Times) The FDA has approved a fixed-dose ophthalmic combination of carbachol and brimonidine tartrate (YUVEZZI; Tenpoint Therapeutics) for the…
FDA approves NDA labeling supplement allowing re-administration of iDose TR | Ophthalmology Times
The US Food and Drug Administration has approved an NDA labeling supplement from Glaukos enabling the re-administration of iDose TR (travoprost intracameral implant) using a repeat treatment protocol. According to the company, under the updated labeling for iDose TR, physicians may now re-administer iDose…
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation | Ophthalmology Times
(Image Credit: ADobeStock/New Africa) A large international study1 that evaluated the properties of dry eye drops showed that the commercially available formulations exhibited varying degrees of shear-thinning behavior, which affects the impact on the ocular surface. Ulrich Graf, PhD, the…
Myra Vision treats first patient in ADAPT trial of Calibreye TGT Surgical System | Ophthalmology Times
(Image Credit: AdobeStock/andrew_shots) Myra Vision has treated the first patient in its ADAPT clinical study evaluating the Calibreye TGT Surgical System in patients with glaucoma. The ADAPT trial is a prospective, multicenter, nonrandomized, open-label study enrolling 70 refractory glaucoma patients…
FDA clears Novaliq’s Investigational New Drug application for NOV05 | Ophthalmology Times
(Image Credit: AdobeStock/Stock Contributor) The US Food and Drug Administration (FDA) has cleared Novaliq’s Investigational New Drug (IND) application for NOV05, enabling the initiation of the EYETAC phase II clinical trial (NCT07285070) in patients with non-infectious anterior uveitis (NIAU). NOV05,…
Dr. Mali’s top 5 predictions in ophthalmology for 2026 | Ophthalmology Times
From artificial intelligence to retinal care and postoperative protection, Joshua Mali, MD, FASRS, offers five predictions shaping ophthalmology in 2026. (Image credit: AdobeStock/Sam Efendi) It’s that exciting time of the year again when I reveal my top 5 predictions in…
Moorfields study reveals sharp rise in glaucoma burden across the UK | Ophthalmology Times
(Image Credit: AdobeStock/Vitalii) A recent press release issued by Moorfields Eye Hospital announced startling glaucoma prevalence data based on a new study1 published in the British Journal of Ophthalmology. The data estimate that the prevalence of glaucoma currently is almost…
SpyGlass Pharma randomizes first patients in 2 phase 3 clinical trials of the BIM-IOL System | Ophthalmology Times
(Image Credit: AdobeStock/Pixel-Shot) SpyGlass Pharma has randomized the first patients in its 2 registrational phase 3 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or…
Rayner announces Sophi Phaco System in the US | Ophthalmology Times
The FDA has given 501(k) clearance to Rayner’s Sophi (Swiss Ophthalmology Innovation) Phacoemulsification System, making it available to cataract surgeons in the US, according to the company.1 The platform was designed with a focus on mobility, simplicity, and safety, which…